HIMS

Hims & Hers Health, Inc. operates in the healthcare sector, focusing on digital health and direct-to-consumer (DTC) telemedicine services. Founded in 2017 and headquartered in San Francisco, California, the company provides online access to medical consultations, prescription treatments and wellness products through an integrated digital platform.

The business model combines telehealth services, licensed healthcare providers and pharmacy fulfillment to deliver treatments directly to consumers.

Its main areas of activity include:

• Telemedicine consultations through digital platforms.
• Prescription treatments for hair loss, dermatology and sexual health.
• Mental-health services, including therapy and psychiatric support.
• Personalized wellness products and subscription-based healthcare programs.

Hims & Hers primarily serves the United States, with services available across all states and the District of Columbia, while also maintaining a presence in the United Kingdom.

The company’s platform connects patients with licensed healthcare professionals, enabling remote consultations and treatment plans supported by partner pharmacies and fulfillment infrastructure.

Industry dynamics are influenced by the rapid adoption of telemedicine, increased consumer demand for personalized healthcare solutions and the expansion of subscription-based healthcare models. Competition includes digital health platforms, telemedicine providers and healthcare technology companies offering remote consultation services.

Shares of Hims & Hers Health, Inc. trade on the Nasdaq under the ticker HIMS.

History and Development

Hims & Hers Health, Inc. was founded in 2017 by Andrew Dudum, Jack Abraham and Hilary Coles with the objective of expanding access to healthcare treatments through digital platforms.

The company initially focused on online treatments for hair loss and dermatology, offering remote consultations and prescription delivery directly to consumers.

As the platform expanded, new services were introduced in areas such as sexual health, mental health and hormone therapy, broadening the scope of its digital healthcare ecosystem.

A major milestone occurred in 2021, when the company became publicly traded through a business combination with Oaktree Acquisition Corp., resulting in its listing on the Nasdaq under the ticker HIMS.

In recent years, Hims & Hers has expanded its treatment portfolio, increased subscription-based services and invested in technology infrastructure designed to support scalable telehealth operations and personalized healthcare delivery.